Bandage-Sized Microneedle Patch Samples Living Immune Cells from Skin Without Blood Draw or Biopsy

Most of what medicine knows about a patient's immune system comes from blood. A blood draw, processed quickly in a clinical lab, reveals circulating immune cell counts, antibody levels, and inflammatory markers. It is fast, standardized, and familiar. It is also incomplete in one critical way: many of the immune cells that matter most for understanding whether a vaccine is working, whether a skin autoimmune condition is active, or whether a cancer therapy is generating a response do not circulate abundantly in blood. They live in tissues - particularly in the skin.

Getting those cells has traditionally meant a biopsy. A skin biopsy is not particularly dangerous, but it is invasive, it leaves a scar, and it is impractical in sensitive locations like the face or neck. For very young children, frail older patients, or anyone requiring repeated sampling over time, it is a significant barrier to immune monitoring.

The study published in Nature Biomedical Engineering describes a different approach: a small, bandage-like patch embedded with hundreds of microscopic needles that can be applied to the skin for a short period and removed. The device harvests immune cells and inflammatory proteins painlessly, without drawing blood and without leaving a wound.

How the Patch Activates the Immune System

The scientific ingenuity in the device lies not in the needles themselves - microneedle patches have been studied for drug delivery for years - but in how it uses the skin's own immune architecture to concentrate the cells researchers need. The patch works by delivering a small amount of a known antigen to the skin surface: a fragment of a virus, an allergen, or a tumor-associated protein. Resident memory T cells - immune sentinels already stationed in the skin from prior exposure to that antigen - recognize it and respond.

That recognition triggers a local alarm: resident memory T cells release signals that recruit additional specialized immune cells from the bloodstream into the skin at the application site. The patch then collects this enriched local population of cells and inflammatory signaling proteins, providing a window into the immune response that blood tests miss.

"Traditionally, studying some of the most important immune cells in the body requires a skin biopsy or blood draws. Because many of these cells live and respond in tissues like the skin, accessing them has meant invasive procedures," said Sasan Jalili, a biomedical engineer and immunologist at The Jackson Laboratory and joint faculty member at UConn School of Medicine. "We've shown we can capture them painlessly and noninvasively instead."

Results in Mouse Models and First Human Test

In mouse vaccination models, the patch dramatically boosted the recovery of antigen-specific T cells compared to blood draws alone, by recruiting cells from the bloodstream to the site of antigen delivery. The effect was substantially larger than would be expected from blood sampling of equivalent volume.

In a human test conducted at UMass Chan Medical School, the patch collected a rich mix of immune cells and signaling proteins including resident memory T cells - the first demonstration of live human immune cell sampling using a microneedle patch, according to the researchers.

"This opens the door to a new way of monitoring immune responses that's practical, painless, and clinically feasible," Jalili said.

Early Stage and Important Caveats

The human data represent a single feasibility demonstration, not a clinical trial. The study has not validated the patch against biopsy results across a range of clinical conditions, nor has it established what immune metrics are clinically meaningful when measured this way. The platform will need prospective studies in defined patient populations - people receiving vaccines, people with psoriasis or vitiligo, cancer patients on immunotherapy - to determine whether the immune data it collects actually predicts outcomes that matter clinically.

The patch is currently a research tool. The path to clinical use requires manufacturing standardization, regulatory approval for diagnostic use, and demonstration of clinical utility beyond proof-of-concept.

Initial applications the researchers envision include monitoring immune responses in aging populations, tracking skin autoimmune conditions like vitiligo and psoriasis, and following vaccine responses in populations where blood draws are difficult - infants, elderly patients, and people with fragile veins. Each application would require its own clinical validation program.